Supplementary Legal Opinion No. 3 on Changzhou Qianhong Biopharmaceutical Co., Ltd.'s Application for Issuing Convertible Bonds to Unspecified Objects
To: Changzhou Qianhong Biopharmaceutical Co., Ltd. (the Issuer)
According to the "Lawyer Service Agreement" signed between our firm and the Issuer, we have accepted the Issuer's commission to act as the special legal advisor for this issuance and hereby issue this supplementary legal opinion. Our lawyers have verified the documents and relevant facts provided by the Issuer in accordance with the provisions of the Company Law, Securities Law, Administrative Measures, Practice Guidelines, and other relevant laws, regulations, rules, and normative documents, and in accordance with the recognized business standards, ethical norms, and diligent spirit of the legal profession. We have issued the following legal opinions: "Legal Opinion on Changzhou Qianhong Biopharmaceutical Co., Ltd.'s Application for Issuing Convertible Bonds to Unspecified Objects" (hereinafter referred to as the "Legal Opinion"), "Lawyer Work Report on Changzhou Qianhong Biopharmaceutical Co., Ltd.'s Application for Issuing Convertible Bonds to Unspecified Objects" (hereinafter referred to as the "Lawyer Work Report"), "Supplementary Legal Opinion No. 1 on Changzhou Qianhong Biopharmaceutical Co., Ltd.'s Application for Issuing Convertible Bonds to Unspecified Objects" (hereinafter referred to as "Supplementary Legal Opinion No. 1"), "Special Verification Report on Changzhou Qianhong Biopharmaceutical Co., Ltd.'s Application for Issuing Convertible Bonds to Unspecified Objects" (hereinafter referred to as the "Special Verification Report"), and "Supplementary Legal Opinion No. 2 on Changzhou Qianhong Biopharmaceutical Co., Ltd.'s Application for Issuing Convertible Bonds to Unspecified Objects" (hereinafter referred to as "Supplementary Legal Opinion No. 2"). The Issuer disclosed its "2025 Annual Report" on April 24, 2026, and the reporting period for this issuance has been adjusted to January 1, 2023, to December 31, 2025.
3-2
According to the "Review Letter [2026] No. 120011" issued by the Shenzhen Stock Exchange regarding the "Inquiry Letter on Changzhou Qianhong Biopharmaceutical Co., Ltd.'s Application for Issuing Convertible Bonds to Unspecified Objects" (hereinafter referred to as the "Inquiry Letter") and at the request of the Issuer, and due to changes in the Issuer's relevant circumstances from October to December 2025, our lawyers have issued this supplementary legal opinion based on further verification of the Issuer and the relevant circumstances of this issuance, modifying, supplementing, or further explaining the relevant content of "Supplementary Legal Opinion No. 1." Our lawyers agree to submit this supplementary legal opinion as a necessary legal document for the Issuer's issuance along with other materials and shall bear corresponding responsibilities in accordance with the law; this supplementary legal opinion is only for the purpose of the Issuer's issuance and shall not be used for any other purpose. The statements made by our lawyers in the "Legal Opinion," "Lawyer Work Report," "Supplementary Legal Opinion No. 1," "Supplementary Legal Opinion No. 2," and "Special Verification Report" also apply to this supplementary legal opinion. Unless otherwise specified, the meanings of terms in this supplementary legal opinion are consistent with those in the "Legal Opinion," "Lawyer Work Report," "Supplementary Legal Opinion No. 1," "Special Verification Report," and "Supplementary Legal Opinion No. 2."
3-3
Our lawyers, in accordance with the requirements of the Company Law, Securities Law, Administrative Measures, Practice Guidelines, and other relevant laws, administrative regulations, rules, and normative documents, as well as the relevant provisions of the China Securities Regulatory Commission and the stock exchange, and in accordance with the recognized business standards, ethical norms, and diligent spirit of the legal profession, hereby issue the following supplementary legal opinions: